- Home
- ECBK vs SKYE Comparison
ECBK vs SKYE Comparison
Compare ECBK & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECBK
- SKYE
- Stock Information
- Founded
- ECBK 1919
- SKYE 2012
- Country
- ECBK United States
- SKYE United States
- Employees
- ECBK N/A
- SKYE N/A
- Industry
- ECBK Banks
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- ECBK Finance
- SKYE Health Care
- Exchange
- ECBK Nasdaq
- SKYE Nasdaq
- Market Cap
- ECBK 123.9M
- SKYE 108.3M
- IPO Year
- ECBK N/A
- SKYE N/A
- Fundamental
- Price
- ECBK $14.33
- SKYE $3.65
- Analyst Decision
- ECBK
- SKYE Buy
- Analyst Count
- ECBK 0
- SKYE 6
- Target Price
- ECBK N/A
- SKYE $18.67
- AVG Volume (30 Days)
- ECBK 14.7K
- SKYE 596.8K
- Earning Date
- ECBK 11-07-2024
- SKYE 11-09-2024
- Dividend Yield
- ECBK N/A
- SKYE N/A
- EPS Growth
- ECBK 74.17
- SKYE N/A
- EPS
- ECBK 0.42
- SKYE N/A
- Revenue
- ECBK $24,752,000.00
- SKYE N/A
- Revenue This Year
- ECBK N/A
- SKYE N/A
- Revenue Next Year
- ECBK N/A
- SKYE N/A
- P/E Ratio
- ECBK $34.39
- SKYE N/A
- Revenue Growth
- ECBK 2.68
- SKYE N/A
- 52 Week Low
- ECBK $9.82
- SKYE $1.44
- 52 Week High
- ECBK $14.84
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- ECBK 59.48
- SKYE 38.57
- Support Level
- ECBK $14.31
- SKYE $3.46
- Resistance Level
- ECBK $14.66
- SKYE $3.92
- Average True Range (ATR)
- ECBK 0.31
- SKYE 0.47
- MACD
- ECBK -0.01
- SKYE 0.02
- Stochastic Oscillator
- ECBK 64.36
- SKYE 24.65
About ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.